Physician profile
James C Major
NPI 1700076783
$28,498.32
in general payments reported to CMS, 2019-2025
16 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $77.08 · 2021: $221 · 2022: $384 · 2023: $5,134 · 2024: $5,961 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,320 · Consulting Fee: $3,817 · Food and Beverage: $2,430 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,320.17 |
| Consulting Fee | $3,816.75 |
| Food and Beverage | $2,429.51 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $7,342.15 | 2019-2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $6,951.75 | 2019-2023 | Eylea |
| Regeneron Healthcare Solutions, INC. | $5,895.72 | 2019-2025 | Eylea Hd, Eylea |
| Ocular Therapeutix, INC. | $2,865.00 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,500.00 | 2019 | |
| Alimera Sciences, INC. | $1,454.84 | 2020-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $403.91 | 2022-2025 | Syfovre |
| Astellas Pharma US INC | $363.38 | 2023-2025 | Izervay |
| Abbvie INC. | $289.95 | 2023-2025 | |
| Biogen, INC. | $115.28 | 2022-2024 | Byooviz |
| Allergan, INC. | $89.90 | 2019 | |
| Coherus Oncology, INC. | $74.95 | 2023 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.48 | 2019 | |
| Ani Pharmaceuticals, INC. | $23.68 | 2025 | Yutiq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $19.57 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Major listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.